Blockade of voltage-gated calcium channel Cav1.2 and α1-adrenoceptors increases vertebral artery blood flow induced by the antivertigo agent difenidol.

Difenidol (1,1-diphenyl-4-piperidino-1-butanol hydrochloride) is an effective drug for the treatment of vertigo and dizziness. This drug is known to improve the blood flow in vertebral arteries, though the precise mechanism underlying this action remains unclear. In the present study, we investigated the effect of difenidol on voltage-gated calcium channel Ca(v)1.2 and α(1)-adrenoceptor subtypes that regulate the intracellular calcium concentration ([Ca(2+)](i)), as well as their possible involvement in the action of difenidol on vertebral artery relaxation and blood flow in dogs. In vitro binding assays demonstrated that difenidol at micromolar concentrations bound to the α(1A)-, α(1B)- and α(1D)-adrenoceptor subtypes. Difenidol inhibited the phenylephrine-induced increase in [Ca(2+)](i) in Chinese hamster ovary cells expressing human α(1A)-, α(1B)- or α(1D)-adrenoceptor subtypes with similar IC(50) values in the low micromolar range. In an electrophysiological assay, difenidol inhibited L-type calcium channel (Ca(v)1.2 subunit). In dogs, i.v. difenidol preferentially enhanced vertebral over femoral arterial blood flow. Phenylephrine and potassium induced contraction of dog vertebral arterial rings, and difenidol inhibited this action. Inhibition of phenylephrine-induced contraction by difenidol was mimicked by the α(1)-adrenoceptor antagonist phentolamine, the α(1A)-adrenoceptor antagonist RS 17,053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-α,α-dimethyl-1H-indole-3-ethanamine hydrochloride) and the α(1D)-adrenoceptor antagonist BMY 7378 (8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4,5]decane-7,9-dione dihydrochloride). In addition, the L-type calcium channel blocker nifedipine, like difenidol, attenuated the potassium-induced contraction. These findings suggest that the difenidol-induced increase in vertebral arterial blood flow may be due to vascular relaxation mediated by mixed blocking actions at α(1)-adrenoceptors and voltage-gated calcium channel Ca(v)1.2.

[1]  A. Goetz,et al.  BMY 7378 is a selective antagonist of the D subtype of α1-adrenoceptors , 1995 .

[2]  Management of the patient with chronic dizziness. , 2010, Restorative neurology and neuroscience.

[3]  A. Evans.  The role of intracellular ion channels in regulating cytoplasmic calciumin pulmonary arterial mmooth muscle: which store and where? , 2010, Advances in experimental medicine and biology.

[4]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[5]  S. Chiba,et al.  Vascular responsiveness of isolated, perfused basilar arteries in dogs and monkeys. , 1985, The Tohoku journal of experimental medicine.

[6]  K. Minneman,et al.  Coupling efficiencies of human alpha 1-adrenergic receptor subtypes: titration of receptor density and responsiveness with inducible and repressible expression vectors. , 1996, Molecular pharmacology.

[7]  J. McGrath,et al.  A knockout approach indicates a minor vasoconstrictor role for vascular alpha1B-adrenoceptors in mouse. , 2002, Physiological genomics.

[8]  M. Ohkura,et al.  Inhibitory effect of lomerizine, a prophylactic drug for migraines, on serotonin-induced contraction of the basilar artery. , 2009, Journal of pharmacological sciences.

[9]  G. Silverberg,et al.  Noradrenaline receptors on the rat basilar artery. , 1982, The Journal of physiology.

[10]  T. Stamey,et al.  RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification. , 1996, Molecular pharmacology.

[11]  N. Klugbauer,et al.  Dominant role of smooth muscle L‐type calcium channel Cav1.2 for blood pressure regulation , 2003, The EMBO journal.

[12]  Anne W. Schmidt,et al.  Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds. , 1991, Journal of medicinal chemistry.

[13]  Ji Soo Kim,et al.  Inner ear dysfunction due to vertebrobasilar ischemic stroke. , 2009, Seminars in neurology.

[14]  K. Sugita,et al.  Increased Ca2+ Influx in the Resting State Maintains the Myogenic Tone and Activates Charybdotoxin-Sensitive K+ Channels in Dog Basilar Artery , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  C. Hung,et al.  Diphenidol inhibited sodium currents and produced spinal anesthesia , 2010, Neuropharmacology.

[16]  J. Liao,et al.  Role of angiotensin II receptor subtypes in porcine basilar artery: functional, radioligand binding, and cell culture studies. , 2006, Life sciences.

[17]  A. Bronstein,et al.  The social impact of dizziness in London and Siena , 2010, Journal of Neurology.

[18]  T. Futaki,et al.  Meniere's Disease and Diphenidol , 1975 .

[19]  A. Goetz,et al.  BMY 7378 is a selective antagonist of the D subtype of alpha 1-adrenoceptors. , 1995, European journal of pharmacology.

[20]  T. Ishikawa,et al.  Ionic mechanism for contractile response to hyposmotic challenge in canine basilar arteries. , 2005, American journal of physiology. Cell physiology.

[21]  R. Lefkowitz,et al.  International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. , 1995, Pharmacological reviews.

[22]  Julie A Simpson,et al.  The prevalence of ear, nose and throat problems in the community: results from a national cross-sectional postal survey in Scotland. , 2005, Family Practice.

[23]  Q. Ye,et al.  Flunarizine blocks voltage-gated Na+ and Ca2+ currents in cultured rat cortical neurons: A possible locus of action in the prevention of migraine , 2011, Neuroscience Letters.

[24]  M. Eltze,et al.  Failure of AH11110A to functionally discriminate between α1-adrenoceptor subtypes A, B and D or between α1- and α2-adrenoceptors , 2001 .

[25]  M. Morimoto,et al.  Menière's disease and diphenidol. A critical analysis of symptoms and equilibrium function tests. , 1975, Acta oto-laryngologica. Supplementum.

[26]  K. Minneman,et al.  Recent progress in alpha1-adrenergic receptor research. , 2005, Acta pharmacologica Sinica.

[27]  M. Yanagisawa,et al.  Endothelins: vasoconstrictor effects and localization in canine cerebral arteries , 1991, British journal of pharmacology.

[28]  O. Rascol,et al.  Antivertigo Medications and Drug-Induced Vertigo , 1995, Drugs.

[29]  A. Ford,et al.  Pharmacological characterization of an α1A‐adrenoceptor mediating contractile responses to noradrenaline in isolated caudal artery of rat , 1997, British journal of pharmacology.

[30]  O. Rascol,et al.  Antivertigo medications and drug-induced vertigo. A pharmacological review. , 1995, Drugs.

[31]  D. Isacson,et al.  Epidemiology, co‐morbidity, and impact on health‐related quality of life of self‐reported headache and musculoskeletal pain—a gender perspective , 2004 .

[32]  E. Mackenzie,et al.  Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties. , 1988, The Journal of pharmacology and experimental therapeutics.